Randall L. Woltjer

Randall L. Woltjer

Auto-generated profile, based on publicly available information

Randall L. Woltjer

Oregon Health and Science University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
KJKelley R. Jordan
Kelley R. Jordan
CWCory Wyatt
Cory Wyatt
MFMeghan E. Fallon
Meghan E. Fallon
RWRandy Woltjer
Randy Woltjer
ENEdward A. Neuwelt
Edward A. Neuwelt
KNKhanh P. Nguyen
Khanh P. Nguyen

11 April 2025 in Science Advances
Verified
Journal Article
Open access
MAMoriah R. Arnold
Moriah R. Arnold
GCGabriel M. Cohn
Gabriel M. Cohn
KOKezia Catharina Oxe
Kezia Catharina Oxe
SESomarr N. Elliott
Somarr N. Elliott
CMCynthia Moore
Cynthia Moore
VUVivek Unni
Vivek Unni
Although an increased risk of the skin cancer melanoma in people with Parkinson’s disease (PD) has been shown in multiple studies, the mechanisms involved are poorly understood, but increased expression of the PD-associated protein alpha-synuclein (αSyn) in melanoma cells may be important. Our previous work suggests that αSyn can facilitate DNA double-strand break (DSB) repair, promoting genomic stability. We now show that αSyn is preferentially enriched within the nucleolus in melanoma, where it colocalizes with DNA damage markers and DSBs. Inducing DSBs specifically within nucleolar ribosomal DNA (rDNA) increases αSyn levels near sites of damage. αSyn knockout increases DNA damage within the nucleolus at baseline, after specific rDNA DSB induction, and prolongs the rate of recovery from this induced damage. αSyn is important downstream of ataxia-telangiectasia–mutated signaling to facilitate MDC1-mediated 53BP1 recruitment to DSBs, reducing micronuclei formation and promoting cellular proliferation, migration, and invasion.

11 June 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
RJRamon Barajas Jr.
Ramon Barajas Jr.
DSD. Schwartz
D. Schwartz
HMH.L. McConnell
H.L. McConnell
CKC.N. Kersch
C.N. Kersch
XLXin Li
Xin Li
ENE.A. Neuwelt
E.A. Neuwelt
BACKGROUND AND PURPOSE: Glioblastoma-associated macrophages are a major constituent of the immune response to therapy and are known to engulf the iron-based MR imaging contrast agent, ferumoxytol. Current ferumoxytol MR imaging techniques for localizing macrophages are confounded by contaminating intravascular signal. The aim of this study was to assess the utility of a newly developed MR imaging technique, segregation and extravascular localization of ferumoxytol imaging, for differentiating extravascular-from-intravascular ferumoxytol contrast signal at a delayed 24-hour imaging time point. MATERIALS AND METHODS: Twenty-three patients with suspected post-chemoradiotherapy glioblastoma progression underwent ferumoxytol-enhanced SWI. Segregation and extravascular localization of ferumoxytol imaging maps were generated as the voxelwise difference of the delayed (24 hours) from the early (immediately after administration) time point SWI maps. Continuous segregation and extravascular localization of ferumoxytol imaging map values were separated into positive and negative components. Image-guided biologic correlation was performed. RESULTS: Negative segregation and extravascular localization of ferumoxytol imaging values correlated with early and delayed time point SWI values, demonstrating that intravascular signal detected in the early time point persists into the delayed time point. Positive segregation and extravascular localization of ferumoxytol imaging values correlated only with delayed time point SWI values, suggesting successful detection of the newly developed extravascular signal. CONCLUSIONS: Segregation and extravascular localization of ferumoxytol MR imaging improves on current techniques by eliminating intrinsic tissue and intravascular ferumoxytol signal and may inform glioblastoma outcomes by serving as a more specific metric of macrophage content compared with uncorrected T1 and SWI techniques.

15 December 2023 in Platelets
Verified
Journal Article
Open access
RMRick Mathews
Rick Mathews
NSNaly Setthavongsack
Naly Setthavongsack
ALAnh Le-Cook
Anh Le-Cook
AKAndy Kaempf
Andy Kaempf
JLJennifer Loftis
Jennifer Loftis
KNKhanh P Nguyen
Khanh P Nguyen
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.

24 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SVSelina M. Vattathil
Selina M. Vattathil
DDDuc M. Duong
Duc M. Duong
MGMarla Gearing
Marla Gearing
NSNicholas T. Seyfried
Nicholas T. Seyfried
RWRobert S. Wilson
Robert S. Wilson
AWAliza Wingo
Aliza Wingo
Behavioral and psychological symptoms of dementia (BPSD) are common, profoundly troubling to patients and caregivers, and difficult to treat, yet their molecular underpinnings remain poorly understood. Here, we generated a large brain proteomic dataset with nine BPSD domains assessed in life from 376 donors from three cohorts. Protein associations with BPSD were examined using complementary approaches — domain-specific BPSD, multi-domain BPSD, and latent factor modeling — and integrated via cross-cohort meta-analysis. Four proteins (NMT1, DCAKD, DNPH1, and HIBADH) were associated with anxiety in dementia and five proteins (ABL1, SAP18, PLXND1, CTRB2, and LDHD) with multi-domain BPSD or BPSD latent factors after adjusting for sex, age, and other covariates (FDR < 0.05). Additionally, eight protein co-expression networks were associated with BPSD across cohorts. Together, these results link BPSD to dysregulation of synaptic signaling, protein folding, and humoral immune response, providing a molecular framework for therapeutic discovery.

1 March 2026 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
RMRick Mathews
Rick Mathews
MHMonica T. Hinds
Monica T. Hinds
RWRandall L. Woltjer
Randall L. Woltjer
AMAshok Muralidaran
Ashok Muralidaran